



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Evolocumab

| | |
|-----------|---|
| Cat. No.: | HY-P9930 |
| CAS No.: | 1256937-27-5 |
| Target: | NF-κB; Ser/Thr Protease; Toll-like Receptor (TLR) |
| Pathway: | NF-κB; Metabolic Enzyme/Protease; Immunology/Inflammation |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|--|
| Description | Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H ₂ O ₂ -induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation ^{[1][2][3]} . |
| IC₅₀ & Target | PCSK9 ^[1] |
| In Vitro | Evolocumab (5-100 μg/mL) can significantly prevent the cytotoxicity of H ₂ O ₂ on human umbilical vein endothelial cells (HUVEC) ^[2] . Evolocumab (100 μg/mL) can reduce the expression and secretion of inflammatory factors increased by stimulation of rat retinal Müller cells (RMC) ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

CUSTOMER VALIDATION

- Biochem Pharmacol. 2023 Dec 26:115996.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Fala L, et al. Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia. Am Health Drug Benefits. 2016 Mar;9(Spec Feature):136-9.
- [2]. Zhou Q, et al. Protective effect of evolocumab on Müller cells in the rat retina under hyperglycaemic and hypoxic conditions. J Diabetes Complications. 2023 Oct;37(10):108593.
- [3]. Safaeian L, et al. Evolocumab, a PCSK9 inhibitor, protects human endothelial cells against H₂O₂-induced oxidative stress. Arch Physiol Biochem. 2022 Dec;128(6):1681-1686.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA